Latest news with #EverestMedicines
Associated Press
2 days ago
- Business
- Associated Press
Everest Medicines to Announce 2025 Interim Results on August 29, 2025
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim results for the six months ended June 30, 2025, and provide a business update on August 29, 2025. The Company will hold live conference calls in English and Mandarin on August 29, 2025, Beijing Time. The English session of the conference call will be held at 8:00 AM on August 29, 2025, Beijing Time (8:00 PM U.S. Eastern Time on August 28, 2025), and the Mandarin session of the conference call will be held at 9:30 AM Beijing Time on the same day (9:30 PM U.S. Eastern Time on August 28, 2025). The conference calls can be accessed by the following links: For English Session: Time: 8:00 AM Beijing Time, Friday, August 29, 2025 (8:00 PM U.S. Eastern Time, Thursday, August 28, 2025) Pre-Registration Link: Webcast Link: Alternatively, participants may dial in to the conference call using below dial-in information: For Mandarin Session: Time: 9:30 AM Beijing Time, Friday, August 29, 2025 (9:30 PM U.S. Eastern Time, Thursday, August 28, 2025) Webcast Link: Alternatively, participants may dial into the conference call using below dial-in information: The replay of English session will be available shortly after the call and can be accessed by visiting the Company's website at About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at Forward-Looking Statements: This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'confident' and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. View original content: SOURCE Everest Medicines
Yahoo
6 days ago
- Business
- Yahoo
3 Asian Value Stocks Estimated To Be Up To 48.2% Below Intrinsic Value
As global markets grapple with renewed trade tensions and economic uncertainties, Asian equities present a mixed landscape, with some indices experiencing declines amid these challenges. In this environment, identifying undervalued stocks becomes crucial as investors seek opportunities that may offer potential value relative to their intrinsic worth. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Xiaocaiyuan International Holding (SEHK:999) HK$10.24 HK$20.31 49.6% Xi'an NovaStar Tech (SZSE:301589) CN¥157.18 CN¥311.35 49.5% Ningbo Sanxing Medical ElectricLtd (SHSE:601567) CN¥22.79 CN¥45.51 49.9% Inspur Digital Enterprise Technology (SEHK:596) HK$10.34 HK$20.38 49.3% Insource (TSE:6200) ¥918.00 ¥1816.18 49.5% Hibino (TSE:2469) ¥2402.00 ¥4707.69 49% Heartland Group Holdings (NZSE:HGH) NZ$0.80 NZ$1.59 49.7% GEM (SZSE:002340) CN¥6.53 CN¥12.95 49.6% Devsisters (KOSDAQ:A194480) ₩46700.00 ₩93201.12 49.9% cottaLTD (TSE:3359) ¥441.00 ¥867.59 49.2% Click here to see the full list of 273 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Everest Medicines Overview: Everest Medicines Limited is a biopharmaceutical company focused on discovering, licensing, developing, and commercializing therapies and vaccines for critical unmet medical needs in Greater China and other Asia Pacific markets, with a market cap of HK$25.51 billion. Operations: The company generates revenue of CN¥706.68 million from its pharmaceuticals segment, focusing on therapies and vaccines in Greater China and other Asia Pacific regions. Estimated Discount To Fair Value: 33.2% Everest Medicines is trading at HK$72.7, significantly below its estimated fair value of HK$108.8, indicating potential undervaluation based on cash flows. The company recently raised HK$1.57 billion through a follow-on equity offering and has promising growth prospects with expected annual earnings growth of over 100%. Everest's NEFECON drug has received full approval in China for treating IgA nephropathy, enhancing its revenue potential as it expands into Asian markets. Our comprehensive growth report raises the possibility that Everest Medicines is poised for substantial financial growth. Delve into the full analysis health report here for a deeper understanding of Everest Medicines. Wuxi Zhenhua Auto PartsLtd Overview: Wuxi Zhenhua Auto Parts Co., Ltd. manufactures and sells auto parts in China, with a market cap of CN¥8.32 billion. Operations: Wuxi Zhenhua Auto Parts Co., Ltd. generates revenue through the production and distribution of automotive components within China. Estimated Discount To Fair Value: 48.2% Wuxi Zhenhua Auto Parts Ltd. is trading at CN¥33.9, significantly below its estimated fair value of CN¥65.45, showcasing potential undervaluation based on cash flows. The company anticipates revenue growth of 20.5% annually, outpacing the broader Chinese market's 12.6%. However, its dividend yield of 1.74% is not well covered by free cash flows, and while earnings are expected to grow significantly over the next three years, return on equity remains modest at a forecasted 18.7%. Our earnings growth report unveils the potential for significant increases in Wuxi Zhenhua Auto PartsLtd's future results. Click to explore a detailed breakdown of our findings in Wuxi Zhenhua Auto PartsLtd's balance sheet health report. Kunshan Kinglai Hygienic MaterialsLtd Overview: Kunshan Kinglai Hygienic Materials Co., Ltd. (SZSE:300260) operates in the hygienic materials sector, with a market capitalization of approximately CN¥14.45 billion. Operations: The company generates its revenue from various segments, including hygienic materials and related products. Estimated Discount To Fair Value: 37.1% Kunshan Kinglai Hygienic Materials Ltd. is trading at CN¥35.61, well below its estimated fair value of CN¥56.63, indicating substantial undervaluation based on cash flow analysis. The company's earnings and revenue are projected to grow significantly over the next three years, with earnings expected to increase by 47.86% annually, outpacing the broader Chinese market's growth rates. Despite this potential, it carries a high level of debt and recently approved a modest dividend payout for 2024. Upon reviewing our latest growth report, Kunshan Kinglai Hygienic MaterialsLtd's projected financial performance appears quite optimistic. Take a closer look at Kunshan Kinglai Hygienic MaterialsLtd's balance sheet health here in our report. Make It Happen Get an in-depth perspective on all 273 Undervalued Asian Stocks Based On Cash Flows by using our screener here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1952 SHSE:605319 and SZSE:300260. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
09-06-2025
- Business
- Yahoo
June 2025's Asian Stock Picks Estimated Below Fair Value
As global markets navigate a complex landscape marked by trade tensions and economic shifts, Asian markets have shown resilience, with Chinese stocks gaining ground amid expectations of government stimulus. In this environment, identifying undervalued stocks can be a strategic approach for investors seeking opportunities below fair value, especially when considering factors such as market sentiment and macroeconomic developments. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥38.99 CN¥76.64 49.1% Taiyo Yuden (TSE:6976) ¥2411.50 ¥4741.52 49.1% Livero (TSE:9245) ¥1692.00 ¥3352.54 49.5% Kanto Denka Kogyo (TSE:4047) ¥841.00 ¥1677.13 49.9% Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) CN¥16.67 CN¥33.21 49.8% Gushengtang Holdings (SEHK:2273) HK$38.35 HK$76.50 49.9% Fuji (TSE:6134) ¥2253.50 ¥4448.27 49.3% Everest Medicines (SEHK:1952) HK$54.55 HK$107.01 49% Brangista (TSE:6176) ¥597.00 ¥1180.86 49.4% Boditech Med (KOSDAQ:A206640) ₩15850.00 ₩31439.92 49.6% Click here to see the full list of 302 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Underneath we present a selection of stocks filtered out by our screen. Overview: BYD Company Limited, along with its subsidiaries, operates in the automobiles and batteries sectors across China, Hong Kong, Macau, Taiwan, and internationally, with a market cap of approximately HK$1.17 trillion. Operations: BYD's revenue is primarily derived from its operations in the automobiles and batteries sectors, serving markets in China, Hong Kong, Macau, Taiwan, and internationally. Estimated Discount To Fair Value: 28.2% BYD is trading at HK$132.2, significantly below its estimated fair value of HK$184.06, indicating potential undervaluation based on cash flows. The company has demonstrated robust earnings growth of 47.2% over the past year and anticipates future revenue growth of 13.2% annually, outpacing the Hong Kong market average. Recent developments include a substantial dividend payout approved at their AGM and expansion plans in Europe, which could further enhance BYD's financial performance and market position in the EV sector. Upon reviewing our latest growth report, BYD's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of BYD stock in this financial health report. Overview: Everest Medicines Limited is a biopharmaceutical company focused on discovering, licensing, developing, and commercializing therapies and vaccines for critical unmet medical needs in Greater China and other Asia Pacific markets, with a market cap of HK$17.70 billion. Operations: The company's revenue segment includes Pharmaceuticals, generating CN¥706.68 million. Estimated Discount To Fair Value: 49% Everest Medicines is trading at HK$54.55, significantly below its estimated fair value of HK$107.01, suggesting potential undervaluation based on cash flows. The company anticipates a robust revenue growth rate of 29.8% annually, surpassing the Hong Kong market average. Recent product approvals for NEFECON in China and positive trial results for EVER001 underscore its strategic advancements in nephrology treatments, though profitability challenges remain with a net loss reported at CNY 1.04 billion last year. In light of our recent growth report, it seems possible that Everest Medicines' financial performance will exceed current levels. Click to explore a detailed breakdown of our findings in Everest Medicines' balance sheet health report. Overview: Bosideng International Holdings Limited operates in the apparel business in the People's Republic of China, with a market cap of HK$51.78 billion. Operations: The company's revenue segments include Down Apparels generating CN¥20.66 billion, Ladieswear Apparels contributing CN¥735.22 million, Diversified Apparels at CN¥254.12 million, and Original Equipment Manufacturing (OEM) Management bringing in CN¥2.97 billion. Estimated Discount To Fair Value: 23.2% Bosideng International Holdings is trading at HK$4.52, below its estimated fair value of HK$5.89, highlighting potential undervaluation based on cash flows. The company's earnings grew by 41.4% last year and are projected to grow 12.92% annually, outpacing the Hong Kong market's average growth rate of 10.4%. Despite an unstable dividend track record, analysts agree the stock price could rise by 23.6%, with revenue growth forecasted at 10.9% per year. Our earnings growth report unveils the potential for significant increases in Bosideng International Holdings' future results. Delve into the full analysis health report here for a deeper understanding of Bosideng International Holdings. Dive into all 302 of the Undervalued Asian Stocks Based On Cash Flows we have identified here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1211 SEHK:1952 and SEHK:3998. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
06-06-2025
- Health
- Yahoo
NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat All": — A subanalysis of the NefIgArd study demonstrates that early treatment can more effectively slow disease progression and reduce irreversible nephron loss. — A prospective study indicates that early treatment with NEFECON® in patients diagnosed within 6 months may better control inflammatory responses and delay disease progression. SHANGHAI, June 6, 2025 /PRNewswire/ -- At the 62nd European Renal Association Congress (ERA 2025), nine new studies on NEFECON® were presented, two of which demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy of "Treat the Cause, Treat Early, Treat All". The new results presented at ERA 2025 demonstrate early treatment with NEFECON® can help protect renal function and slow disease progression, leading to improved disease management and an improved quality of life for patients. "The new results have validated the significant role of NEFECON® in the early intervention of IgAN, and have fully demonstrated its key value in the strategy of 'Treat the Cause, Treat Early, Treat All'." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, "These findings further underscore its outstanding clinical advantages as a first-line cornerstone therapy for IgAN. The 'Treat Early' strategy offers more proactive treatment for IgAN patients, helping to control disease progression and better protect renal function. NEFECON® is the first and only fully approved etiological treatment for IgAN in China, the U.S., and Europe, providing patients with new hope and treatment options. "The new findings provide robust evidence for early targeted intervention. They show that NEFECON® significantly reduces proteinuria and protect kidney function across all diagnostic timelines, with the greatest improvements in eGFR observed in patients diagnosed within 0.6 years." Professor Ping Fu from West China Hospital of Sichuan University commented, " This demonstrates that early treatment can more effectively slow disease progression and reduce irreversible nephron loss. Additionally, early treatment with NEFECON® in patients diagnosed within 6 months may better control inflammatory responses and delay disease progression. The Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review) also recommends NEFECON® as the preferred treatment to reduce Gd-IgA1. These results emphasize the importance of early treatment for IgAN and provide valuable guidance for clinical practice." The new results provide a strong evidence-based support for NEFECON®'s variable effects depending on treatment timing and disease duration. In a subanalysis of the NefIgArd study[1], which assessed the renal benefits of budesonide delayed-release capsules (16 mg/day) across different diagnostic timelines, 364 primary IgAN patients were stratified into quartiles based on time since biopsy-confirmed diagnosis. Results showed that NEFECON® preserved eGFR and reduced UPCR versus placebo across all quartiles, with the most significant renal protection in recently diagnosed patients. For those diagnosed <0.6 years prior to baseline, NEFECON® increased eGFR by +6.41, +5.78, and +4.79 mL/min/1.73 m² at 9, 12, and 24 months, respectively, and reduced UPCR by 51.12% at 12 months. In a prospective study evaluating the impact of budesonide on inflammatory processes in recently diagnosed versus long-standing IgAN patients[2], eligible Caucasian adults were divided into two groups: recent diagnosis (RD, n=8, ≤6 months) and established diagnosis (OD, n=6, >6 months). The RD group showed a significant increase in CLU levels from 48.38 pg/ml at baseline (T0) to 94.92 pg/ml at 3 months (T3) (p=0.036), while no significant change was observed in the OD group. This suggests that early NEFECON® treatment may modulate the renal immune microenvironment, triggering protective protein expression (e.g., CLU) to repair damage. Moreover, eGFR in the RD group gradually improved from T0 to T10, indicating better renal preservation with early intervention. NEFECON®, as the only in-disease IgAN treatment has been included in the KDIGO 2024 Clinical Practice Guideline For The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV) (public review draft), making it the only targeted therapy endorsed by both international and Chinese guidelines. About NEFECON® NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models. In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in mainland China, Hong Kong, Macau, Taiwan (China) and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicines' territories. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at Forward-Looking Statements: This press release may contain forward-looking statements based on current expectations, involving risks and uncertainties. Actual results may differ materially due to various factors. The company undertakes no obligation to update these statements unless required by law. References: 1. Lafayette R, et al. Abstract#3251-Nefecon provides kidney benefit irrespective of time since diagnosis in patients with IgAN: a subanalysis of the NefIgArd study. Presented at ERA 2025. 2. Keskinis C, et al. Abstract#2093-Targeted-Release Budesonide (TRB) treatment may have different effects on the inflammatory process in IgAN patients with recent and old diagnosis. Presented at ERA 2025. View original content: SOURCE Everest Medicines Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Health
- Yahoo
Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)
SHANGHAI, May 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, announced that NEFECON® has been included in the "Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)" (hereinafter referred to as the "Guideline (Draft)") on May 21, recommending the etiological treatment with a 9-month course of NEFECON® for all primary immunoglobulin A nephropathy (IgAN) patients who are at risk for disease progression, irrespective of proteinuria levels (2B). The Guideline (Draft) was presented by Professor Hong Zhang and Professor Jicheng Lv from Peking University First Hospital, during the IgA Nephropathy Forum and IIgANN-China Annual Meeting. It aims to provide crucial guidance for the standardization and optimization of IgA nephropathy diagnosis and treatment. The Guideline (Draft) emphasizes a new disease management strategy of Treat the cause, Treat early, Treat comprehensively. The Guideline (Draft) recommends that patients with proteinuria ≥ 0.5g/day (or equivalent levels) undergo a renal biopsy and initiate treatment. The treatment goal is to slow the estimated glomerular filtration rate (eGFR) loss to less than 1 ml/min per year. In addition to the two core indicators of proteinuria and eGFR, the Guideline (Draft) also emphasizes routine monitoring of hematuria. For the first time, the guideline introduces interventions targeting immune-mediated injury, particularly the formation of pathogenic IgA (Gd-IgA1), a key driver of pathogenesis to IgAN. For patients at risk of disease progression, the guideline proposes addressing both symptoms of renal function decline, and initiating therapies targeting immune-mediated injury and CKD progression. NEFECON® is recommended as the preferred treatment to reduce Gd-IgA1. Once short-term treatment goals, namely proteinuria remission (defined as proteinuria < 0.5 g/day, ideally < 0.3 g/day) and stable renal function, are achieved, low-dose maintenance or repeated safe and effective immunotherapy can be considered together with supportive care to ensure that eGFR declines by less than 1 ml/min per year. "Compared to European and American populations, China has a large IgAN patient population. Chinese IgAN patients experience more rapid disease progression and poorer prognosis. A majority of IgAN patients face the risk of progressing to end-stage renal disease during their lifetime, placing a heavy burden on patients and society." Said Professor Zhang Hong with Peking University First Hospital, a member of the global steering committee for the Phase 3 clinical trial NefIgArd, chairman of the Chinese Collaborative Group of the International IgAN Federation. "Therefore, IgAN patients require early diagnosis, and a comprehensive treatment approach that spans early intervention, initial therapy, and maintenance therapy. The Guideline (Draft) offers important guidance for clinical practice of IgA nephropathy treatment in China." "IgA nephropathy is the most common form of chronic glomerulonephritis worldwide, affecting 40% to 50%[1,2] of kidney biopsy patients in Asian populations, particularly in China. Fifteen years after diagnosis, the kidney survival rate can drop to as low as 40%[1]. This makes the development of guidelines tailored to the Chinese population particularly important." said Professor Jicheng Lv from Peking University First Hospital. "The Guideline (Draft) updates the treatment strategies and medications for IgAN in China, further standardizing its diagnosis and treatment. It establishes a novel care strategy for Chinese IgAN patients, emphasizing the principles of Treat the cause, Treat early, Treat comprehensively. It recommends treatment with a 9-month course of NEFECON® for IgAN patients at risk of disease progression (2B)." "We are delighted to see NEFECON® included in the Guideline (Draft), marking a milestone that not only provides Chinese physicians a scientific and precise treatment option but also promises greater benefits and improved quality of life for Chinese IgAN patients." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "As the first and only etiological treatment for IgAN fully approved in China, the United States, and Europe, NEFECON® significantly slows eGFR decline, reduces proteinuria, and preserves kidney function. NEFECON® has established itself as a first-line cornerstone therapy for IgAN. Its inclusion in the draft guideline further validates its outstanding clinical advantages, redefining treatment standards and entering a new era of standardized care." NEFECON®, as the only in-disease IgA nephropathy (IgAN) treatment has been included in the "KDIGO 2024 Clinical Practice Guideline For The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV) (public review draft), recommending treatment with a 9-month course of NEFECON® for patients who are at risk of progressive kidney function loss with IgAN (2B). Results from the Phase 3 clinical study NefIgArd of the Chinese population shows that NEFECON® reduces kidney function decline by 66%, and delays disease progression to dialysis or kidney transplantation by 12.8 years. During the 2-year treatment and observation period, NEFECON® also demonstrated clinically significant kidney function protection. With the Phase 3 clinical study and real-world evidence, NEFECON® not only fills the gap in etiological treatment for IgAN both domestically and internationally, but also provides clinicians with more compelling treatment options, giving patients a valuable treatment window. Since May 2025, NEFECON® is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, irrespective of proteinuria levels. This approval marks NEFECON® as the first and only etiological treatment for IgA nephropathy (IgAN) to receive full approval in China. NEFECON® was also included in the National Reimbursement Drug List in November 2024. About NEFECON® NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models. In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in mainland China, Hong Kong, Macau, Taiwan (China) and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicines' territories. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at Forward-Looking Statements: This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. References: 1. Shen X, et al. Nephrol Dial Transplant. 2024 Nov 19: gfae252. 2. Li G, et al. J Nephrol . 2025 Mar 26. doi: 10.1007/s40620-025-02261-1. Online ahead of print. View original content: SOURCE Everest Medicines Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
